CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Enrolling by invitation · NCT07168486 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Richter transformation, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm | Enrolling by invitation | Phase 1 | 2026-09-14 | NCT07168486 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Maryland, Baltimore | 198 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Maryland, Baltimore | Baltimore | United States | 32 |